Recurrent Respiratory Tract Infections
7
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
1 terminated out of 7 trials
66.7%
-19.8% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children
Prospective Multicentre Study on Symptoms in First-onset Bronchial Asthma in Children and Adolescents
Evaluation of Lactobacillus Reuteri DSM 17938 + Vitamin D3 in the Prevention of RRI in Paediatric Patients
Evaluate the Effect of Nasal Spray in the Prevention of RTI in Children With Pre-school Wheezing
Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)
Clinical and Laboratory Predictors of Respiratory Morbidities in CP Children
Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.